COUGH is the #8 most commonly reported adverse reaction for MOMETASONE FUROATE, manufactured by L. Perrigo Company. There are 2,666 FDA adverse event reports linking MOMETASONE FUROATE to COUGH. This represents approximately 2.5% of all 107,848 adverse event reports for this drug.
MOMETASONE FUROATE has an overall safety score of 78 out of 100. Patients taking MOMETASONE FUROATE who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
COUGH2,666 of 107,848 reports
COUGH is a less commonly reported adverse event for MOMETASONE FUROATE, but still significant enough to appear in the safety profile.
Other Side Effects of MOMETASONE FUROATE
In addition to cough, the following adverse reactions have been reported for MOMETASONE FUROATE:
COUGH has been reported as an adverse event in 2,666 FDA reports for MOMETASONE FUROATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is COUGH with MOMETASONE FUROATE?
COUGH accounts for approximately 2.5% of all adverse event reports for MOMETASONE FUROATE, making it a notable side effect.
What should I do if I experience COUGH while taking MOMETASONE FUROATE?
If you experience cough while taking MOMETASONE FUROATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.